share_log

Uncovering Potential: PDS Biotechnology's Earnings Preview

Uncovering Potential: PDS Biotechnology's Earnings Preview

揭示潛力:pds biotechnology 的收益預覽
Benzinga ·  11/14 00:02

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.

pds生物技術(納斯達克:PDSB)將於2024年11月14日星期四發佈最新的季度業績。投資者在公佈前需要了解以下內容。

Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.28.

分析師預計pds生物技術將報告每股收益(EPS)爲-0.28美元。

The announcement from PDS Biotechnology is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

投資者急切期待pds生物技術的公告,希望獲得超越預期的消息和下一季度的有利指引。

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

值得注意的是,對於新投資者來說,指導可能是股票價格波動的關鍵因素。

Past Earnings Performance

過去的盈利表現

Last quarter the company beat EPS by $0.11, which was followed by a 0.98% drop in the share price the next day.

上一季度該公司每股收益超過0.11美元,隨後第二天股價下跌了0.98%。

Here's a look at PDS Biotechnology's past performance and the resulting price change:

這裏是pds生物技術過去表現和導致的股價變動。

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate -0.34 -0.37 -0.44 -0.45
EPS Actual -0.23 -0.30 -0.35 -0.35
Price Change % -1.0% 1.0% 3.0% 1.0%
季度 2024年第二季度 2024年第一季度 Q4 2023 Q3 2023
每股收益預估值 -0.34 -0.37 -0.44 -0.45
每股收益實際值 -0.23 -0.30 -0.35 -0.35
價格變更% -1.0% 1.0% 3.0% 1.0%
bigjpg

Stock Performance

股票表現

Shares of PDS Biotechnology were trading at $2.96 as of November 12. Over the last 52-week period, shares are down 56.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

pds生物技術的股價截至11月12日爲2.96美元。在過去的52周裏,股價下跌了56.38%。鑑於這些回報通常爲負面,長期股東可能會看淡這次業績發佈。

To track all earnings releases for PDS Biotechnology visit their earnings calendar on our site.

要追蹤pds生物技術的所有業績,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文是由Benzinga的自動內容引擎生成,並由編輯審核。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論